I n a research study reported Thursday, a medication from Bristol Myers Squibb almost doubled the treatment advantage compared to basic treatment for particular clients with a persistent blood condition called myelodysplastic syndrome– results that might alter the method doctors look after these clients.
Myelodysplastic syndrome, or MDS, is a cancer-like illness of the bone marrow that leads to reduced production of healthy blood cells. As it advances, clients end up being vulnerable to infections and extreme anemia that can need persistent blood transfusions.
The Bristol research study, called COMMANDS, set out to figure out whether preliminary treatment with Reblozyl, which promotes the maturation of late-stage red cell, would benefit individuals with lower-risk, transfusion-dependent MDS more than usage of so-called erythropoietin-stimulating representatives, or ESAs, that promote the production of early-stage red cell and are the existing requirement of care.
Open this short article by registering for STAT+ and enjoy your very first thirty days complimentary!